Hospira 1Q Revenues: $884.0 million (-9%) 1Q Loss: $76.6 million (earnings were $40.2 million 1Q12) Comments: Specialty Injectable Pharmaceuticals sales were $651.5 million, up 11%. Medication Management revenues dropped 51% to $124.5 million. Other Pharma sales were $108.0 million, down 12%. Certain quality and product related charges primarily include third party oversight and consulting costs, extended production downtime related costs, failure to supply penalties, device product review an...